MGMonica Galliano

Monica Galliano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Galliano has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Variations in the Human Serum Albumin Gene: Molecular and Functional Aspects

    by Gianluca Caridi, Francesca Lugani, Andrea Angeletti, Monica Campagnoli, Monica Galliano, Lorenzo Minchiotti

    The human albumin gene, the most abundant serum protein, is located in the long arm of chromosome 4, near the centromere, position 4q11–3. It is divided by 14 intervening introns into 15 exons, the last of which is untranslated. To date, 74 nucleotide substitutions (mainly missense) have been reported, determining the circulating variants of albumin or pre-albumin. In a heterozygous state, this condition is known as alloalbuminaemia or bisalbuminaemia (OMIM # 103600). The genetic variants are not associated with disease, neither in the heterozygous nor in the homozygous form. Only the variants resulting in familial dysalbuminaemic hyperthyroxinaemia and hypertriiodothyroninaemia are of clinical relevance because affected individuals are at risk of inappropriate treatment or may have adverse drug effects. In 28 other cases, the pathogenic variants (mainly affecting splicing, nonsense, and deletions), mostly in the homozygous form, cause a premature stop in the synthesis of the protein and lead to the condition known as congenital analbuminaemia. In this review, we will summarize the current knowledge of genetic and molecular aspects, functional consequences and potential therapeutic uses of the variants. We will also discuss the molecular defects resulting in congenital analbuminaemia, as well as the biochemical and clinical features of this rare condition


  • Open Access

    Clinical, Genetic, and Protein Structural Aspects of Familial Dysalbuminemic Hyperthyroxinemia and Hypertriiodothyroninemia

    by Ulrich Kragh-Hansen, Monica Galliano, Lorenzo Minchiotti

    Familial dysalbuminemic hyperthyroxinemia (FDH-T4) and hypertriiodothyroninemia (FDH-T3) are dominantly inherited syndromes characterized by a high concentration of thyroid hormone in the blood stream. The syndromes do not cause disease, because the concentration of free hormone is normal, but affected individuals are at risk of erroneous treatment. FDH-T4 is the most common cause of euthyroid hyperthyroxinemia in Caucasian populations in which its prevalence is about 1 in 10,000 individuals, but the prevalence can be much higher in some ethnic groups. The condition is caused by a genetic variant of human serum albumin (HSA); Arg218 is mutated to histidine, proline or serine or Arg222 is changed to isoleucine. The disorder is characterized by greater elevation in serum L-thyroxine (T4) than in serum triiodothyronine (T3); T4 can be increased by a factor 8 ‒ 15. The high serum concentration of T4 is due to modification of a binding site located in the N-terminal half of HSA (in subdomain IIA). Thus, mutating Arg218 or Arg222 for a smaller amino acid reduces the steric restrictions in the site and creates a high-affinity binding site. The mutations can also affect binding of other ligands and can perhaps cause modified pharmacokinetics of albumin-binding drugs. In normal HSA, the high-affinity site has another location (in subdomain IIIB). Different locations of these sites imply that persons with and without FDH-T4 can have different types of interactions, and thereby complications, when given albumin-binding drugs. FDH-T3 is caused by a leucine to proline mutation in position 66 of HSA, which results in a large increment of the binding affinity for T3 but not for T4. For avoiding unwanted treatment of euthyroid persons with hyperthyroxinemia or hypertriiodothyroninemia, protein sequencing and/or sequencing of the albumin gene should be performed.


  • A two-base-pairs deletion in the albumin gene causes a new case of analbuminemia

    by Gianluca Caridi, Monica Dagnino, Marco Di Duca, Saikat Santra, Sarah Ball, Raashda A. Sulaiman, Monica Campagnoli, Monica Galliano, Lorenzo Minchiotti


  • A novel splicing mutation causes analbuminemia in a Portuguese boy

    by Gianluca Caridi, Monica Dagnino, Marco Di Duca, Helena Pinto, Maria Do Céu Espinheira, António Guerra, Susana Fernandes, Monica Campagnoli, Monica Galliano, Lorenzo Minchiotti


  • Open Access

    Molecular Diagnosis of Analbuminemia: A New Case Caused by a Nonsense Mutation in the Albumin Gene

    by Monica Dagnino, Gianluca Caridi, Ueli Haenni, Adrian Duss, Fabienne Aregger, Monica Campagnoli, Monica Galliano, Lorenzo Minchiotti

    Analbuminemia is a rare autosomal recessive disorder manifested by the absence, or severe reduction, of circulating serum albumin (ALB). We report here a new case diagnosed in a 45 years old man of Southwestern Asian origin, living in Switzerland, on the basis of his low ALB concentration (0.9 g/L) in the absence of renal or gastrointestinal protein loss, or liver dysfunction. The clinical diagnosis was confirmed by a mutational analysis of the albumin (ALB) gene, carried out by single-strand conformational polymorphism (SSCP), heteroduplex analysis (HA), and DNA sequencing. This screening of the ALB gene revealed that the proband is homozygous for two mutations: the insertion of a T in a stretch of eight Ts spanning positions c.1289 + 23–c.1289 + 30 of intron 10 and a c.802 G > T transversion in exon 7. Whereas the presence of an additional T in the poly-T tract has no direct deleterious effect, the latter nonsense mutation changes the codon GAA for Glu244 to the stop codon TAA, resulting in a premature termination of the polypeptide chain. The putative protein product would have a length of only 243 amino acid residues instead of the normal 585 found in the mature serum albumin, but no evidence for the presence in serum of such a truncated polypeptide chain could be obtained by two dimensional electrophoresis and western blotting analysis.


  • Open Access

    Albumin Benkovac (c.1175 A > G; p.Glu392Gly): a novel genetic variant of human serum albumin

    by Gianluca Caridi, Monica Dagnino, Ana-Maria Simundic, Marijana Miler, Vladimir Stancic, Monica Campagnoli, Monica Galliano, Lorenzo Minchiotti


  • Open Access

    Identification of the amniotic fluid insulin‐like growth factor binding protein‐1 phosphorylation sites and propensity to proteolysis of the isoforms

    by Lorenzo Dolcini, Alberto Sala, Monica Campagnoli, Sara Labò, Maurizia Valli, Livia Visai, Lorenzo Minchiotti, Hugo L. Monaco, Monica Galliano

    Insulin-like growth factor binding protein-1 (IGFBP-1) is the major secreted protein of human decidual cells during gestation and, as a modulator of insulin-like growth factors or by independent mechanisms, regulates embryonic implantation and growth. The protein is phosphorylated and this post-translational modification is regulated in pregnancy and represents an important determinant of its biological activity. We have isolated, from human normal amniotic fluid collected in the weeks 16–18, the intact nonphosphorylated IGFBP-1 and five electrophoretically distinct phosphoisoforms and have determined their in vivo phosphorylation state. The unmodified protein was the most abundant component and mono-, bi-, tri- and tetraphosphorylated forms were present in decreasing amounts. The phosphorylation sites of IGFBP-1 were identified by liquid chromatography–tandem mass spectrometry analysis of the peptides generated with trypsin, chymotrypsin and Staphylococcus aureus V8 protease. Five serines were found to be phosphorylated and, of these, four are localized in the central, weakly conserved, region, at positions 95, 98, 101 and 119, whereas one, Ser169, is in the C-terminal domain. The post-translational modification predominantly involves the hydrophilic stretch of amino acids representing a potential PEST sequence (proline, glutamic acid, serine, threonine) and our results show that the phosphorylation state influences the propensity of IGFBP-1 to proteolysis.


  • Analbuminemia in a Swedish male is caused by the Kayseri mutation (c228_229delAT)

    by Monica Campagnoli, Per Hansson, Lorenzo Dolcini, Gianluca Caridi, Monica Dagnino, Giovanni Candiano, Maurizio Bruschi, Lars Palmqvist, Monica Galliano, Lorenzo Minchiotti


  • Mapping the 5–50‐kDa fraction of human amniotic fluid proteins by 2‐DE and ESI‐MS

    by Elisabetta Gianazza, Robin Wait, Shaina Begum, Ivano Eberini, Monica Campagnoli, Sara Labò, Monica Galliano

    This report presents a proteomic analysis and provides a reference map of the 5–50‐kDa components of normal amniotic fluid collected in gestational weeks 16–18. Early amniocentesis samples were pooled and proteins with molecular mass lower than albumin were separated by gel filtration chromatography. The 2‐DE protocol was optimized for the separation of the small proteins and peptides in the fraction of interest. A total of 132 Coomassie blue‐stained protein spots were analyzed, following in‐gel tryptic digestion, by ESI‐MS/MS and 49 different gene products were identified. The treatment with alkaline phosphatase caused the shift of the phosphoisoforms of insulin‐like growth factor‐binding protein‐1 and of the N‐terminal osteopontin fragment. Of the 33 full‐length proteins identified in the 2‐DE profile, 23 had not been previously detected in the amniotic fluid and, of these, 22 are not present in the human plasma proteome under physiological conditions. Fragments of 16 larger proteins were identified and the sequence coverage data revealed that several correspond to autonomous domains that may have biological roles on their own. Several of the detected proteins and peptides appear to be involved in critical regulatory processes associated with placentation and early development, thus representing potential markers of various physiological or pathological conditions.


  • Open Access

    Structure and Properties of the C-terminal Domain of Insulin-like Growth Factor-binding Protein-1 Isolated from Human Amniotic Fluid

    by Alberto Sala, Stefano Capaldi, Monica Campagnoli, Beniamino Faggion, Sara Labò, Massimiliano Perduca, Assunta Romano, Maria E. Carrizo, Maurizia Valli, Livia Visai, et al.